948894-26-6

Basic information

• Product Name: 4-Methylpiperidine-4-carbonitrile hydrochloride
• Synonyms: 4-Methylpiperidine-4-carbonitrile hydrochloride;4-Cyano-4-methylpiperidine hydrochloride;4-piperidinecarbonitrile, 4-methyl-, hydrochloride (1:1);4-CYANO-4-METHYLPIPERIDINE HCL
• CAS NO: 948894-26-6
• Molecular Formula: C₇H₁₂N₂*ClH
• Molecular Weight: 160.64452
• Mol File: 948894-26-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Methylpiperidine-4-carbonitrile hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methylpiperidine-4-carbonitrile hydrochloride(948894-26-6)
• EPA Substance Registry System: 4-Methylpiperidine-4-carbonitrile hydrochloride(948894-26-6)

Safety Data

• Hazardous Substances Data: 948894-26-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Methylpiperidine-4-carbonitrile hydrochloride is used as an intermediate in the synthesis of active pharmaceutical ingredients (APIs) for the development of new drugs. Its role in the production of APIs is crucial, as it contributes to the formulation of medications that address a wide range of health conditions.
Used in Agrochemical Industry:
In the field of agricultural chemistry, 4-Methylpiperidine-4-carbonitrile hydrochloride may also have applications, potentially serving as a precursor in the development of agrochemicals that enhance crop protection and yield. Its versatility in chemical synthesis allows for its use in creating compounds that can be tailored to specific agricultural needs.
Used as a Building Block in Chemical Synthesis:
4-Methylpiperidine-4-carbonitrile hydrochloride is utilized as a valuable building block in the synthesis of complex molecular structures. Its importance lies in its ability to be incorporated into a variety of chemical frameworks, facilitating the creation of innovative and effective pharmaceutical and agrochemical products.

Upstream product

• 343788-67-0 4-carbamoyl-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 407-25-0 trifluoroacetic anhydride 
• 530115-96-9 4-cyano-4-methylpiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 948894-28-8 8-(benzyloxy)-5-{(1R)-1-{[tert-butyl(dimethyl)silyl]oxy}-2-[({4-methyl-1-[2-(2-phenylethoxy)ethyl]piperidin-4-yl}methyl)amino]ethyl}quinolin-2(1H)-one 
• 948894-30-2 8-(benzyloxy)-5-{(1R)-1-hydroxy-2-[({4-methyl-1-[2-(2-phenylethoxy)ethyl]piperidin-4-yl}methyl)amino]ethyl}quinolin-2(1H)-one 
• 948894-29-9 1-{4-methyl-1-[2-(2-phenylethoxy)ethyl]piperidin-4-yl}methanamine 
• 948894-27-7 4-methyl-1-[2-(2-phenylethoxy)ethyl]piperidine-4-carbonitrile 

Relevant articles and documents

N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS

The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 9936396.1

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention al

BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula wherein the combination of R1 and R2 are

PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS

The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.